All In Biotech

Drug Trial Radar · NCT02464670

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

May 2015

Primary completion

May 24, 2018

Study completion May 24, 2018

Sponsor

Lead sponsor
Inovio PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
GeneOne Life Science, Inc.; Defense Advanced Research Projects Agency
First posted
Jun 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.

Conditions

  • Ebola Vaccine

Interventions

  • INO-4201Biological

    INO-4201 delivered IM followed by Electroporation

  • INO-4202Biological

    INO-4202 delivered IM followed by Electroporation

  • INO-4201Biological

    INO-4201 delivered ID followed by Electroporation

  • INO-4212Biological

    INO-4212 delivered IM followed by Electroporation

  • INO-4212 + INO-9012Biological

    INO-4212 + INO-9012 delivered IM followed by Electroporation

  • INO-4201 + INO-9012Biological

    INO-4201 + INO-9012 delivered ID followed by Electroporation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Assessment (Composite of multiple measures: adverse events, pain (VAS), lab abnormalities, changes in vital signs)Time frame: Screening through up to 60 weeks following the first dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • QPS MRA

    Miami, Florida

  • The Center for Pharmaceutical Research

    Kansas City, Missouri

  • University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.